News
23

The Atlantic Cancer Research Institute congratulates Dr. Adrian Culf, a research scientist at ACRI, who has received a $25,000 New Brunswick Health Research Foundation (NBHRF) grant to make and laboratory test histone deacetylase (HDAC) inhibitors – novel molecules as a potentially useful anti-cancer treatment. HDAC's are more numerous in cancers, making them promising target proteins for cancer therapy.

This grant is the latest in a series of three over the past year to fund this area of Dr. Culf's research. Said Dr. Culf, "This is very much a team effort with the work of other research scientists, research assistants, technicians and students at ACRI as well as collaborations at other NB-based centres: the National Research Council of Canada (NRC), Université de Moncton and Mount Allison University as co-applicants on these successful grants."

"Dr. Culf's research is advancing our ability to therapeutically target specific molecules, like the HDACs, that drive cancer development and progression, "says Dr. Stephen Lewis, Assistant Scientific Director at ACRI. "The financial support provided by NBHRF will allow Dr. Culf to continue to develop his HDAC inhibitors, and I expect that he will make some interesting and exciting discoveries in this field in the near future."

Media coverage :

Twitter

Archived Articles

btn campain EN
Atlantic Cancer Research Institute 
Pavillon Hôtel-Dieu
35, Providence Street
Moncton, NB E1C 8X3 Canada

info@canceratl.ca
Tel.: 506-862-7512
Fax.: 506-862-7571

Annual Report 2017 Cover
Our annual report
Download PDF bullet blanc

The Atlantic Cancer Research Institute

 (ACRI) is a non-profit organization founded in late 1998 and housed at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton. Thanks to its unique expertise, ACRI has become a true centre of excellence in cancer research.

Our Partners

logo excipio logo chudumont logo soricimedlogo neplogo ccslogo umonctonlogo unblogo vitalitelogo conceptiaCRS logoNBHRF logoMerck Logo.svg